Latest Breaking News On - Guoxin guotong - Page 1 : comparemela.com

杭汽轮Ｂ(200771):股份转让受让方简式权益变动报告书内容的补充公告(英文）- CFi CN 中财网

杭汽轮Ｂ(200771):股份转让受让方简式权益变动报告书内容的补充公告(英文）- CFi CN 中财网
cfi.net.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cfi.net.cn Daily Mail and Mail on Sunday newspapers.

Li weishuZhou yueLiu jingquanGuo xiaoyuWang shaolongDai yusiLiu weiLi yananHangzhou liangzhu cultural city group co ltdZhejiang jinkong investment management co ltdChina guoxin holdings co ltdHangzhou weitong equity investment partnership limitedAdministration commission of hangzhou municipal people governmentCo ltdHangzhou botong business management co ltdHang zhou iron steel co ltd

These were the biggest clinical trial operations deals in the three months to August 2021

These were the biggest clinical trial operations deals in the three months to August 2021
clinicaltrialsarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicaltrialsarena.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesCzech republicArnold pharmaRosen katzArnold bioAdlai nortye biopharmaEli lillyGuoxin guotongArnold bio pharmaAurinia pharmaDuowei haituoAdlai nortye biopharma coKirkland ellisJjdc incBaupost group

China s Stemirna raises $188M to fund mRNA COVID-19 vaccine

China’s Stemirna Therapeutics has raised RMB 1.2 billion ($188 million) to bankroll development of an mRNA vaccine against COVID-19. Sequoia Capital China co-led the financing with backers including WuXi AppTec plus assists from OrbiMed and other investors.

South africaGuoxin guotongLi hangwenFosun pharmaHealthcare industry equity fundStemirna therapeuticsCapital chinaWuxi apptecChina merchants medicalAdvantech capitalTsing song capitalSequoia capitalWuxi apptecStemirna therapeuticsMessenger rnaCovid 19

Sequoia China co-leads $188m round in Covid vaccine developer Stemirna

Sequoia China co-leads $188m round in Covid vaccine developer Stemirna Photo: National Cancer Institute/Unsplash June 3, 2021 mRNA driven drugs and vaccines maker Stemirna Therapeutics on Thursday announced that it has raked in 1.2 billion yuan ($188 million) in a new funding round jointly led by Sequoia Capital China, state-backed China Merchants Medical and Healthcare Industry Equity Fund, Chinese global pharma major WuXi AppTec and Greenwoods Investment. The round also saw participation from a slew of investors including New York-based OrbiMed Healthcare Fund Management, China-focused Advantech Capital, China Reform Holdings’ sub-fund Guoxin Guotong, China Merchants Bank’s CMB International, Efund, Forebright, Tsing Song Capital, and CITIC Securities.

South africaGuoxin guotongLi hangwenOrbimed healthcare fund managementChina merchants bankChinese centerSchool of shanghai tongji universityChina reform holdingHealthcare industry equity fundStemirna therapeuticsSequoia capital chinaChina merchants medicalWuxi apptecNew york based orbimed healthcare fund managementChina focused advantech capitalTsing song capital